The effect of Cabergolin on pelvic pain in endometriosis

Comparison of the impact of Cabergolin and a placebo on pelvic pain after laparoscopic surgery in cases of endometriosis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20091012002576N39

Enrollment

200

Registered

2024-03-29

Start date

2024-04-03

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis. Endometriosis of pelvic peritoneum

Interventions

Intervention 1: Intervention group: After laparoscopy for endometriosis, Cabergolin 0.5 mg/week, Aboreihan Company plus dinogest 2.5 mg /daily for 3 months will be prescribed then pelvic pain evaluat

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Approved endometriosis by pathology Presence good quality embryo

Exclusion criteria

Exclusion criteria: Hypersensitivity to cbergoline BMI>30 Diabetes melitus Hydrosalpinx Severe male factor AMH<1

Design outcomes

Primary

Measure	Time frame
Pelvic pain. Timepoint: Before and three months after surgery. Method of measurement: VAS questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Davari Tanha

Tehran University of Medical Sciences

Fatedavtanha@gmail.com+98 21 8880 0115

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026